Noxopharm Ltd has released a press release.
DARRT-2 Study Update and Clarification
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- Noxopharm Set to Benefit From Novartis ASCO Data
- New Independent Trial Data Supports Potential of Veyonda
- Veyonda to Begin First-Line Sarcoma Treatment Testing
- Veyonda FDA Approved Trial to Commence
- Publications Positive Review of Veyonda in Chemotherapy
Later from Noxopharm
- Noxopharm Secures Key European Patent Allowance for Veyonda
- DARRT-2 Study Receives IND Approval from FDA
- June 2021 Quarterly Activities Report and Appendix 4C
- Veyonda Survival Advantage in LuPSMA Therapy Confirmed
- NOX and US Govt Peak Cancer Agency Announce Collaboration
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm